220 related articles for article (PubMed ID: 32473354)
1. Racial disparity in Covid-19 mortality rates - A plausible explanation.
Tal Y; Adini A; Eran A; Adini I
Clin Immunol; 2020 Aug; 217():108481. PubMed ID: 32473354
[No Abstract] [Full Text] [Related]
2. Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis.
Quan C; Li C; Ma H; Li Y; Zhang H
Clin Microbiol Rev; 2020 Oct; 34(1):. PubMed ID: 33055229
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
Ratajczak MZ; Kucia M
Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
[TBL] [Abstract][Full Text] [Related]
4. The "Three Italy" of the COVID-19 epidemic and the possible involvement of SARS-CoV-2 in triggering complications other than pneumonia.
Prezioso C; Marcocci ME; Palamara AT; De Chiara G; Pietropaolo V
J Neurovirol; 2020 Jun; 26(3):311-323. PubMed ID: 32548750
[TBL] [Abstract][Full Text] [Related]
5. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV.
Kadambari S; Klenerman P; Pollard AJ
Rev Med Virol; 2020 Sep; 30(5):e2144. PubMed ID: 32671966
[TBL] [Abstract][Full Text] [Related]
6. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
7. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
8. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
9. COVID-19 and Hypercoagulability.
Sholzberg M
Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
[No Abstract] [Full Text] [Related]
10. Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients.
Xu ZS; Shu T; Kang L; Wu D; Zhou X; Liao BW; Sun XL; Zhou X; Wang YY
Signal Transduct Target Ther; 2020 Jun; 5(1):100. PubMed ID: 32561706
[No Abstract] [Full Text] [Related]
11. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
Tavakolpour S; Rakhshandehroo T; Wei EX; Rashidian M
Immunol Lett; 2020 Sep; 225():31-32. PubMed ID: 32569607
[No Abstract] [Full Text] [Related]
12. COVID 19: a clue from innate immunity.
Birra D; Benucci M; Landolfi L; Merchionda A; Loi G; Amato P; Licata G; Quartuccio L; Triggiani M; Moscato P
Immunol Res; 2020 Jun; 68(3):161-168. PubMed ID: 32524333
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
14. Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019.
Huang L; Zhao X; Qi Y; Li H; Ye G; Liu Y; Zhang Y; Gou J
Cell Mol Immunol; 2020 Oct; 17(10):1092-1094. PubMed ID: 32917983
[No Abstract] [Full Text] [Related]
15. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
Xi Y
Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
[No Abstract] [Full Text] [Related]
16. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
Costela-Ruiz VJ; Illescas-Montes R; Puerta-Puerta JM; Ruiz C; Melguizo-RodrÃguez L
Cytokine Growth Factor Rev; 2020 Aug; 54():62-75. PubMed ID: 32513566
[TBL] [Abstract][Full Text] [Related]
17. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
Chrousos GP; Meduri GU
Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
[No Abstract] [Full Text] [Related]
18. Treating COVID-19 with colchicine in community healthcare setting.
Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
[No Abstract] [Full Text] [Related]
19. Covid-19: Perspectives on Innate Immune Evasion.
Taefehshokr N; Taefehshokr S; Hemmat N; Heit B
Front Immunol; 2020; 11():580641. PubMed ID: 33101306
[TBL] [Abstract][Full Text] [Related]
20. Storm of soluble immune checkpoints associated with disease severity of COVID-19.
Kong Y; Wang Y; Wu X; Han J; Li G; Hua M; Han K; Zhang H; Li A; Zeng H
Signal Transduct Target Ther; 2020 Sep; 5(1):192. PubMed ID: 32895366
[No Abstract] [Full Text] [Related]
[Next] [New Search]
